{"id":4120,"date":"2026-05-26T08:00:00","date_gmt":"2026-05-26T02:30:00","guid":{"rendered":"https:\/\/www.inbody.in\/blog\/?p=4120"},"modified":"2026-06-01T05:35:12","modified_gmt":"2026-06-01T05:35:12","slug":"pcod-management-body-composition-india","status":"publish","type":"post","link":"https:\/\/www.inbody.in\/blog\/pcod-management-body-composition-india","title":{"rendered":"PCOD Management in India \u2014 What Body Composition Tells You"},"content":{"rendered":"\n
<\/p>\n\n\n\n
Roughly 1 in 5 Indian women of reproductive age has PCOD or PCOS<\/strong> \u2014 among the highest prevalence in the world (AIIMS 2024 cohort data). Most of them have been told the same first instruction: “lose weight.” For about a third of them, this advice is unhelpful and for a meaningful share it is actively wrong, because their weight is not the problem. Their body composition<\/em> is. Modern PCOD management<\/strong> takes the focus off the scale and puts it on three or four specific numbers \u2014 and the results, when measured correctly, are dramatically different.<\/p>\n\n\n\n
PCOD \u2260 PCOS \u2014 what most Indian women aren’t told<\/h2>\n\n\n\n<\/figure>\n\n\n\n
The terms PCOD and PCOS are often used interchangeably in India, but they refer to overlapping (not identical) conditions:<\/p>\n\n\n\n
\n
PCOD (Polycystic Ovarian Disease)<\/strong> \u2014 a more functional, hormone-based condition. Ovaries release immature\/partial eggs that become small cysts; cycles are irregular but ovulation often still occurs. Common, generally manageable with lifestyle and body composition correction.<\/li>\n\n\n\n
PCOS (Polycystic Ovarian Syndrome)<\/strong> \u2014 a metabolic-endocrine syndrome (Rotterdam criteria: 2 of 3 \u2014 irregular cycles, hyperandrogenism, polycystic ovaries on ultrasound). Often associated with insulin resistance, metabolic syndrome, and infertility. Needs endocrinology input.<\/li>\n<\/ul>\n\n\n\n
Both share a common upstream driver in most Indian women: insulin resistance.<\/strong> And insulin resistance is the single most measurable thing on a body composition scan.<\/p>\n\n\n\n
\n
Key Takeaways<\/strong><\/p>\n
\n
1 in 5 Indian women of reproductive age has PCOD\/PCOS \u2014 one of the highest rates globally.<\/li>\n
“Lose weight” misses the point: PCOD is upstream of weight; insulin resistance and body composition come first.<\/li>\n
Visceral fat + skeletal muscle mass predict symptom severity better than BMI.<\/li>\n
30% of Indian women with PCOD have a “normal” BMI \u2014 they often get the wrong first-line advice.<\/li>\n
A 6-month plan focused on body composition (not weight) puts most patients into symptom improvement.<\/li>\n<\/ul>\n<\/div>\n\n\n\n
Why “lose weight” is the wrong first instruction<\/h2>\n\n\n\n<\/figure>\n\n\n\n
The standard PCOD prescription in Indian general-practice clinics goes: “Your weight is the problem. Lose 5\u201310% body weight. Symptoms will improve.” This advice is sometimes correct and often misleading. Three reasons:<\/p>\n\n\n\n
It misses lean PCOD entirely.<\/strong> About 30% of Indian PCOD patients have a BMI under 25 \u2014 the “lean PCOD” or “thin PCOD” subset. Telling these women to “lose weight” is not just unhelpful; if they crash-diet, they lose muscle mass and worsen their underlying insulin resistance.<\/p>\n\n\n\n
It rewards the wrong tissue loss.<\/strong> A patient who follows a low-calorie, low-protein crash diet may drop 4 kg on the scale \u2014 but 2 kg of that is muscle. Muscle is the body’s primary glucose-disposal tissue. Lose muscle, and insulin resistance gets worse<\/em>, even as weight goes down.<\/p>\n\n\n\n
It hides the visceral fat story.<\/strong> Many normal-weight Indian PCOD patients have high visceral fat (the dangerous abdominal-deep fat). Visceral fat is hormonally active and is the part that drives PCOD symptoms \u2014 but it does not show up cleanly on a scale.<\/p>\n\n\n\n
The right first instruction is: measure your body composition, treat the insulin resistance, and let the weight reorganise itself.<\/strong><\/p>\n\n\n\n
Insulin resistance is the upstream problem<\/h2>\n\n\n\n
In most Indian PCOD patients, this sequence runs the show:<\/p>\n\n\n\n
\n
Visceral fat accumulates (often without overall weight gain \u2014 see “thin-fat Indian” phenotype)<\/li>\n\n\n\n
Visceral fat releases inflammatory cytokines that interfere with insulin signalling<\/li>\n\n\n\n
Insulin resistance develops; the pancreas compensates by producing more insulin<\/li>\n\n\n\n
High circulating insulin stimulates the ovaries to produce more androgens (male hormones)<\/li>\n\n\n\n
Elevated androgens disrupt the menstrual cycle, drive acne and hair growth, and prevent ovulation<\/li>\n<\/ol>\n\n\n\n
You will notice that “weight” is not anywhere in this chain. Visceral fat<\/strong> and insulin resistance<\/strong> are. The right tools for PCOD are the ones that measure those two things directly.<\/p>\n\n\n\n
The 4 body composition markers that track PCOD better than BMI<\/h2>\n\n\n\n\n
Visceral Fat Level (1\u201320).<\/strong> Target under 10. Most PCOD patients sit at 11\u201315 \u2014 even at normal BMI. This is the single most actionable number.<\/li>\n\n\n\n
Skeletal Muscle Mass (kg).<\/strong> The glucose-disposal infrastructure. Building 2\u20133 kg of muscle over 6\u201312 months meaningfully improves insulin sensitivity and often regularises cycles.<\/li>\n\n\n\n
Body Fat Percentage (Asian-adjusted).<\/strong> Healthy: under 30% for adult Indian women. Many “normal BMI” PCOD patients are at 32\u201338% \u2014 clinically overfat, biochemically explanatory.<\/li>\n\n\n\n
Phase Angle.<\/strong> Cell-membrane integrity marker. Reflects systemic inflammation. Tends to improve weeks before lab values do \u2014 early indicator that you are on the right track.<\/li>\n<\/ol>\n\n\n\n
A typical case (illustrative)<\/h2>\n\n\n\n
Illustrative example \u2014 composite based on typical patient profiles.<\/em><\/p>\n\n\n\n
A 27-year-old in New Delhi, BMI 23 (textbook “normal”). Diagnosed PCOD at 22, irregular cycles, acne, mild hirsutism. Her gynaecologist’s first advice was “lose 4 kg” \u2014 but she had no weight to lose. Body composition scan five years into the condition shows: visceral fat level 13 (high), skeletal muscle 19.2 kg (low for her height), body fat 34% (above Asian threshold despite normal BMI). The plan changes from “lose weight” to “lose 5 kg of fat, gain 3 kg of muscle, drop visceral fat to under 10.” Six months of two strength sessions per week, 1.3 g\/kg protein from dal-paneer-egg-tofu, vitamin D correction (her level was 14 \u2014 deficient, very common in Indian women), and her cycles returned to 30\u201332 days. By month 9 she was off metformin. Total scale weight change: \u22121.5 kg. The scale barely moved. Everything else did.<\/em><\/p>\n\n\n\n
What a 6-month PCOD plan actually looks like<\/h2>\n\n\n\n
For a typical Indian PCOD patient with body composition issues:<\/p>\n\n\n\n
Month 1.<\/strong> Baseline body composition scan + standard PCOD blood panel (LH\/FSH, insulin, fasting glucose, HbA1c, Vitamin D, TSH). Start: 1.2 g\/kg protein per day, 2\u00d7 25-min resistance sessions per week, 10K steps\/day, correct any Vitamin D deficiency.<\/p>\n\n\n\n
Months 2\u20133.<\/strong> Phase angle improving on scan. Sleep regularising. Cycle still irregular but mood and energy better. Visceral fat trending down by 1\u20132 points.<\/p>\n\n\n\n
Months 4\u20135.<\/strong> First cycle changes \u2014 most patients see length normalisation around month 4\u20135. Muscle mass up 1\u20131.5 kg. HbA1c (if elevated) starting to drop.<\/p>\n\n\n\n
Month 6.<\/strong> Re-scan. Most patients show: visceral fat down 3\u20135 points, muscle up 2\u20133 kg, fat down 3\u20135 kg, cycles in the 25\u201335 day range. Decision point with your gynaecologist: continue current plan, escalate, or de-escalate medication.<\/p>\n\n\n\n
This trajectory does not work for everyone \u2014 patients with severe insulin resistance, hypothyroidism, or genetic-component PCOS often need pharmacological support (metformin, inositol). But for a large share of PCOD patients in India, body-composition-led management gets to the symptom relief that “lose weight” never did. See also: Lean PCOS \u2014 symptoms and treatment in India<\/a>.<\/p>\n\n\n\n
![\"\"](\"https:\/\/www.inbody.in\/blog\/wp-content\/uploads\/2026\/05\/PCOD-IS-NOT-EQUAL-TO-PCOS-1024x683.webp\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/www.inbody.in\/blog\/wp-content\/uploads\/2026\/05\/Weight-Loss-is-not-the-1st-instruction-for-PCOD-1024x683.webp\")
<\/figure>\n\n\n\n